Purpose . To assess neurocognitive function (NCF), psychosocial outcome, health‐related quality of life (HRQoL), and long‐term effects of immune‐related adverse events (irAE) on metastatic melanoma survivors treated with ipilimumab (IPI). Methods . Melanoma survivors were identified within two study populations ( N = 104), at a single‐center university hospital, and defined as patients who were disease‐free for at least 2 years after initiating IPI. Data were collected using 4 patient‐reported outcome measures, computerized NCF testing, and a semistructured interview at the start and 1‐year follow‐up. Results . Out of 18 eligible survivors, 17 were recruited (5F/12M); median age is 57 years (range 33‐86); and median time since initiating IPI was 5.6 years (range 2.1‐9.3). The clinical interview revealed that survivors suffered from cancer‐related emotional distress such as fear of recurrence ( N = 8), existential problems ( N = 2), survivor guilt ( N = 2), and posttraumatic stress disorder ( N = 6). The mean EORTC QLQ‐C30 Global Score was not significantly different from the European mean of the healthy population. Nine survivors reported anxiety and/or depression (Hospitalization Depression Scale) during the survey. Seven survivors (41%) reported fatigue (Fatigue Severity Scale). Seven patients (41%) had impairment in NCF; only three out of seven survivors had impairment in subjective cognition (Cognitive Failure Questionnaire). Anxiety, depression, fatigue, and neurocognitive symptoms remained stable at the 1‐year follow‐up. All cases of skin toxicity ( N = 8), hepatitis ( N = 1), colitis ( N = 3), and sarcoidosis ( N = 1) resolved without impact on HRQoL. Three survivors experienced hypophysitis; all suffered from persistent fatigue and cognitive complaints 5 years after onset. One survivor who experienced a Guillain‐Barré‐like syndrome suffered from persisting depression, fatigue, and impairment in NCF. Conclusion . A majority of melanoma survivors treated with IPI continue to suffer from emotional distress and impairment in NCF. Timely detection in order to offer tailored care is imperative, with special attention for survivors with a history of neuroendocrine or neurological irAE. The trial is registered with B.U.N. 143201421920.
2034 Background: Patients (pts) with recurrent glioblastoma (rGB) have a poor prognosis, and no treatment option demonstrated to improve survival in a randomized trial. Axitinib (AXI), an oral VEGFR 1-3 inhibitor has demonstrated single agent activity in rGB and reduces the need for corticosteroids (CS). Avelumab (AVE) is a fully human anti-PD-L1 IgG1 antibody with clinical activity in various tumor types. Combination of AXI and AVE may improve the outcome of pts with rGB. Methods: This open-label, dual-strata, single-center phase 2 clinical trial investigated the activity of AXI plus AVE in adult pts with rGB following prior surgery, RT and temozolomide. Pts were stratified according to their baseline use of CS. Pts without baseline need for CS initiated treatment with AXI (5 mg oral BID) plus AVE (10 mg/kg IV Q2W) (cohort-1). Pts in need of CS initiated AXI as a monotherapy; AVE could be added to AXI after 6 wks if the CS dose could be tapered to a physiologic dose level or less (cohort-2). Six-month-PFS served as the primary endpoint (with a prespecified threshold of ≥ 50% for cohort-1) according to Fleming one-stage design. Results: Between Jun 2017 and Aug 2018, 54 pts (27 per cohort) were enrolled (med age 55 y [range 19-75]; 63% male; 91% WHO PS 0-1). All pts in cohort-1 and 16 pts (59%) in cohort-2 received at least 1 dose of AVE. The 6-month-PFS was 18% (95% CI 4-33) in both cohorts. At the time of analysis, 2 pts were progression-free and continuing study treatment. Median OS in cohort-1 and -2 was respectively 26 wks (95% CI 21-32) and 18 wks (95% CI 14-22). No clear relation was found between baseline cognitive functioning (Cogstate subtests) and PFS/OS. The best overall response rate (iRANO) was 41% and 26% respectively for pts in cohort-1 and -2. The most frequent all-grade treatment-related adverse events (TRAE) were dysphonia (67%), lymphopenia (50%), diarrhea (48%), hypertension (48%), and fatigue (46%). The incidence of grade 3-4 TRAE was 30%; there were no grade 5 AE. Conclusions: The combination of AVE plus AXI is sufficiently well tolerated but did not meet the threshold for activity justifying further investigation in an unselected population of patients with rGB. Clinical trial information: NCT03291314.
E14082Background: Both PD-L1 and VEGFR are legitimate therapeutic targets in recurrent glioblastoma (rGB). Axitinib, a potent, selective small molecule VEGFR 1-3 inhibitor with single-agent activity in rGB, may synergize with the PD-L1 blocking IgG1 mAb avelumab for the treatment of rGB. Methods: A phase II clinical trial investigating avelumab plus axitinib in patients (pts) with rGB is ongoing (NCT03291314). Pts with rGB are stratified according to their baseline use of corticosteroids (CS). Pts without baseline CS use initiated treatment with axitinib (AXI, 5 mg po BID) plus avelumab (AVELU, 10 mg/kg IV Q2w) (Cohort A). Pts with baseline CS use initiated AXI monotherapy (AXI mono); AVELU could be added after 6w if the CS dose could be tapered to ≤ 10 mg prednisolone (Cohort B). Results: From Jun 2017 to Jan 2018, 32 pts (med age 50y [range 29-70]; 62% male; 56% WHO PS 1 or 0) initiated study treatment (16 in Cohort A and 16 in -B) . All pts had failed prior radiotherapy and temozolomide. In Cohort B, 7...
162Background: An increasing proportion of advanced melanoma patients (pts), treated with immune checkpoint inhibitors and/or BRAF/MEK-inhibitors, achieve long-term survival. The traumatic experience of melanoma progression, which often involves the brain, puts them at high risk for emotional and neurocognitive function (NCF) disturbances that may negatively impact their HRQoL. Methods: Pts with advanced melanoma (AJCC stages IIIC or IV) who were in remission for at least 1 year after treatment initiation were included in this ongoing single-center therapeutically non-interventional clinical trial. Data on psychosocial outcome and HRQoL were collected using 6 validated questionnaires, a semi-structured psychiatric examination (SSPE) and a computer based neuro-cognitive function (NCF) test. Results: Test results from the first 24 pts (9M/15F; median age 58y (29-87) were analysed. Mean EORTC Global Health Score was significant lower than the European Mean (t[23]=2.713, p= 0.006). The SSPE revealed that all ...
Recurrent glioblastoma is a devastating disease for which no treatment has demonstrated to improve overall survival in a randomized clinical trial. Anti-tumor Cytolytic T-cell (CTL) activity is suppressed by the CTLA4 and PD-1 immune-checkpoint receptors. Nivolumab(NIVO) is an IgG-4 mAb that blocks PD-1, and ipilimumab(IPI) an IgG-1 mAb that blocks CTLA-4. In a clinical trial for recurrent glioblastoma (BMS CheckMate143), combination of NIVO and IPI administered IV caused unacceptable toxicity. Animal models showed that intratumoral administration of CTLA-4-blocking mAb at a ratio of [1:100] compared to IV-dosing had equivalent anti-tumor effect and was associated with improved tolerability. An ongoing phase I clinical trial for patients with recurrent glioblastoma (rGB) has currently recruited 5 patients: 2M, 3F, median age 60 (range 38-72). Study treatment consists of surgical resection of rGB with injection of IPI (10mg:2ml) (cohort 1 = first 3 patients) or IPI (5mg:1ml) plus NIVO (10mg:1ml) (cohort 2 = 2 patients at present) in the walls of the resection cavity, concomitant with biweekly IV-administration of 10 mg of NIVO x6. Grade 3 AE consisted of epileptic seizures (1pt in cohort 2) and hemiplegia due to accumulation of serosanguinous fluid in the resection cavity (1pt in cohort 2). Additionally, 4/5 patients developed transient grade 1 pyrexia during the postoperative period. Lymphopenia gr 3 was seen in 4/5 patients. All patients have persisting rim-contrast enhancement on MRI. After median follow-up of 22weeks, two patients have progression of disease (after respectively 13 and 19 weeks). All patients are alive. We conclude from these early results that surgical resection of rGB combined with direct intracerebral injection of IPI alone/with NIVO followed by IV administration of NIVO at the doses administered in this trial is feasible and safe. Updated results of this ongoing clinical trial will be presented at the meeting.